ESMO Immuno-Oncology Congress 2019: Scientific Articles & Press Releases

Interested in what happened during the ESMO Immuno-Oncology Congress 2019?

Read all our news here

Date Title Topic
13 Dec 2019 The QuIP Study Attempts to Harmonise the Use of TMB Panels Pathology/Molecular biology - Translational research
13 Dec 2019 BL-8040, Pembrolizumab and Chemotherapy Deliver Promising Disease Control in Patients with Metastatic Pancreatic Adenocarcinoma Gastrointestinal cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
13 Dec 2019 Sitravatinib Plus Tislelizumab Show Promise in Platinum-Resistant Advanced Ovarian Cancer Gynaecologic malignancies - Cancer Immunology and Immunotherapy
12 Dec 2019 First-Line Combination Treatment with Durvalumab Plus Platinum and Etoposide Has Manageable Safety in ES-SCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
12 Dec 2019 First-line Nivolumab Plus Ipilimumab is Safe and Provides Encouraging Survival in Patients with Advanced NSCLC and Co-Morbidity or Poor Performance Status Lung and other thoracic tumours - Cancer in Special Situations / Population - Cancer Immunology and Immunotherapy
12 Dec 2019 Pembrolizumab May Be Considered as a First-Line Treatment Option in Non-Squamous NSCLC Even in the Presence of KRAS Mutations Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
12 Dec 2019 Early Introduction of Corticosteroids May Alter the Efficacy of Immune Checkpoint Inhibitors Lung and other thoracic tumours - Genitourinary cancers - Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
12 Dec 2019 First-line Nivolumab Plus Chemotherapy Did Not Meet the Primary Endpoint of Overall Survival in Non-Squamous NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy